Table 1. Clinical characteristics of the participants enrolled in this study.
| Characteristics | Controls (n = 35) | Primary EOC (n = 35) | Post-operative EOC (n = 35) | Relapsed EOC (n = 35) | P value† |
|---|---|---|---|---|---|
| Age (mean ± SD*) | 53.22 ± 8.30 | 53.67 ± 9.04 | 53.76 ± 9.05 | 54.31 ± 7.28 | 0.9616a |
| Weight (median/range) | 60 (45 ~ 87) | 60 (50 ~ 91.5) | 63.50 (44 ~ 88) | 0.1359b | |
| Menopause (pre/post) | 11/24 | 11/24 | 11/24 | 1.0000c | |
| CA125(median/range) | 17.45 (5.06 ~ 184.5) | 490.80 (67.23 ~ 5000.00)‡ | 95.10 (21.06 ~ 2048.00) | <0.0001b | |
| FIGO Stage (III/IV) | – | 31/4 | 31/4 | 1.0000c | |
| Lymph node metastasis (Yes/No) | – | 20/15 | 17/18 | 0.4726c | |
| Histology differentiation | 0.7936c | ||||
| Well | – | 5 | 4 | ||
| Moderately | – | 11 | 14 | ||
| Poorly | – | 19 | 17 | ||
| Histology type | 0.7022c | ||||
| Serous | – | 27 | 25 | ||
| Mucoid | – | 3 | 2 | ||
| Endometrioid | – | 5 | 8 | ||
*SD: standard deviation.
†P value refers to the statistical significance of differences among or between groups: aOne-way analysis of variance was performed. bNonparametric Kruskal-Wallis rank sum test was performed. cChi-square (χ2) test or Fisher’s exact test was performed.
‡The CA125 value is measured as the pre-operative value.